BACKGROUND AND PURPOSE: alpha5IA (3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine) is a triazolophthalazine with subnanomolar affinity for alpha1-, alpha2-, alpha3- and alpha5-containing GABA(A) receptors. Here we have evaluated the relationship between plasma alpha5IA concentrations and benzodiazepine binding site occupancy in rodents and primates (rhesus monkey). EXPERIMENTAL APPROACH: In awake rats, occupancy was measured at various times after oral dosing with alpha5IA (0.03-30 mgxkg(-1)) using an in vivo {[(3)H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester)} binding assay. In anaesthetized rhesus monkeys, occupancy was measured using {[(123)I]iomazenil (ethyl 5,6-dihydro-7-iodo-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester)} gamma-scintigraphy and a bolus/infusion paradigm. In both rat and rhesus monkey, the plasma drug concentration corresponding to 50% occupancy (EC(50)) was calculated. KEY RESULTS: In rats, alpha5IA occupancy was dose- and time-dependent with maximum occupancy occurring within the first 2 h. However, rat plasma EC(50) was time-independent, ranging from 42 to 67 ngxmL(-1) over a 24 h time course with the average being 52 ngxmL(-1) (i.e. occupancy decreased as plasma drug concentrations fell). In rhesus monkeys, the EC(50) for alpha5IA displacing steady-state [(123)I]iomazenil binding was 57 ngxmL(-1). CONCLUSIONS AND IMPLICATIONS: Rat plasma EC(50) values did not vary as a function of time indicating that alpha5IA dissociates readily for the GABA(A) receptor in vivo. These data also suggest that despite the different assays used (terminal assays of [(3)H]flumazenil in vivo binding in rats and [(123)I]iomazenil gamma-scintigraphy in anaesthetized rhesus monkeys), these techniques produced similar plasma alpha5IA EC(50) values (52 and 57 ngxmL(-1) respectively) and that the plasma-occupancy relationship for alpha5IA translates across these two species.
BACKGROUND AND PURPOSE:alpha5IA (3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine) is a triazolophthalazine with subnanomolar affinity for alpha1-, alpha2-, alpha3- and alpha5-containing GABA(A) receptors. Here we have evaluated the relationship between plasma alpha5IA concentrations and benzodiazepine binding site occupancy in rodents and primates (rhesus monkey). EXPERIMENTAL APPROACH: In awake rats, occupancy was measured at various times after oral dosing with alpha5IA (0.03-30 mgxkg(-1)) using an in vivo {[(3)H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester)} binding assay. In anaesthetized rhesus monkeys, occupancy was measured using {[(123)I]iomazenil (ethyl 5,6-dihydro-7-iodo-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester)} gamma-scintigraphy and a bolus/infusion paradigm. In both rat and rhesus monkey, the plasma drug concentration corresponding to 50% occupancy (EC(50)) was calculated. KEY RESULTS: In rats, alpha5IA occupancy was dose- and time-dependent with maximum occupancy occurring within the first 2 h. However, rat plasma EC(50) was time-independent, ranging from 42 to 67 ngxmL(-1) over a 24 h time course with the average being 52 ngxmL(-1) (i.e. occupancy decreased as plasma drug concentrations fell). In rhesus monkeys, the EC(50) for alpha5IA displacing steady-state [(123)I]iomazenil binding was 57 ngxmL(-1). CONCLUSIONS AND IMPLICATIONS: Rat plasma EC(50) values did not vary as a function of time indicating that alpha5IA dissociates readily for the GABA(A) receptor in vivo. These data also suggest that despite the different assays used (terminal assays of [(3)H]flumazenil in vivo binding in rats and [(123)I]iomazenil gamma-scintigraphy in anaesthetized rhesus monkeys), these techniques produced similar plasma alpha5IA EC(50) values (52 and 57 ngxmL(-1) respectively) and that the plasma-occupancy relationship for alpha5IA translates across these two species.
Authors: G Gründer; F Yokoi; S J Offord; H T Ravert; R F Dannals; J K Salzmann; S Szymanski; P D Wilson; D R Howard; D F Wong Journal: Neuropsychopharmacology Date: 1997-09 Impact factor: 7.853
Authors: M Laruelle; A Abi-Dargham; Z Rattner; M S al-Tikriti; Y Zea-Ponce; S S Zoghbi; D S Charney; J Price; J J Frost; P B Hoffer Journal: Eur J Pharmacol Date: 1993-01-05 Impact factor: 4.432
Authors: A Malizia; G Forse; A Haida; R Gunn; J Melichar; K Poole; D Bateman; D Fahy; L Schnorr; D Brown; C Rhodes; D J Nutt; T Jones Journal: J Psychopharmacol Date: 1995-01 Impact factor: 4.153
Authors: E Sybirska; J P Seibyl; J D Bremner; R M Baldwin; M S al-Tikriti; C Bradberry; R T Malison; Y Zea-Ponce; S Zoghbi; M During Journal: Neuropharmacology Date: 1993-07 Impact factor: 5.250
Authors: P Hantraye; M Kaijima; C Prenant; B Guibert; J Sastre; M Crouzel; R Naquet; D Comar; M Maziere Journal: Neurosci Lett Date: 1984-07-27 Impact factor: 3.046
Authors: David J Nutt; Marie Besson; Susan J Wilson; Gerard R Dawson; Anne R Lingford-Hughes Journal: Neuropharmacology Date: 2007-08-16 Impact factor: 5.250
Authors: Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt Journal: Br J Pharmacol Date: 2018-01-18 Impact factor: 8.739
Authors: Marcia H Ratner; Scott S Downing; Ouyang Guo; KathrynAnn E Odamah; Tara M Stewart; Vidhya Kumaresan; R Jonathan Robitsek; Weiming Xia; David H Farb Journal: Heliyon Date: 2021-09-01
Authors: Joerg F Hipp; Frederic Knoflach; Robert Comley; Theresa M Ballard; Michael Honer; Gerhard Trube; Rodolfo Gasser; Eric Prinssen; Tanya L Wallace; Andreas Rothfuss; Henner Knust; Sian Lennon-Chrimes; Michael Derks; Darren Bentley; Lisa Squassante; Stephane Nave; Jana Nöldeke; Christoph Wandel; Andrew W Thomas; Maria-Clemencia Hernandez Journal: Sci Rep Date: 2021-04-08 Impact factor: 4.379